Clinical Trials Logo

Clinical Trial Summary

Modulation of the renin angiotensin system by the chronic hepatitis C virus treatment either by (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.


Clinical Trial Description

The interaction of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and the renin angiotensin system (RAS) via angiotensin converting enzyme-2 (ACE-2), the receptor used by the SARS-CoV-2 to gain access to cells could provide an explanation for the several unusual clinical findings observed in COVID-19 Although chronic hepatitis is one of the risk factors listed by WHO for severe COVID-19, low incidence of COVID-19 was observed among HCV patients admitted to Egyptian hospitals. Modulation of the RAS by the chronic hepatitis C virus treatment either by (ACEI or ARBS), (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04757272
Study type Observational
Source Zagazig University
Contact
Status Completed
Phase
Start date May 1, 2020
Completion date July 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04578210 - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia Phase 1/Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04720794 - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Completed NCT04598620 - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed NCT05517941 - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient N/A
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Active, not recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT05639998 - BBV152/BBV154 Heterologus Prime-Boost Study Phase 2
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Completed NCT05736926 - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Recruiting NCT04583566 - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04579588 - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Terminated NCT03331445 - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections Phase 2
Recruiting NCT04573348 - T Cells Response to SARS COV 2 Peptides